Given that HVEM has four known ligands, with HVEM-BTLA mediating immunosuppression and HVEM-LIGHT promoting immunostimulation [55], we hypothesized that recombinant HVEM protein could exert anti-tumor effects by preferentially interacting with BTLA and thus interfering with the HVEM-BTLA pathway. Here, TNFRSF14 is linked to neoplasm.